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Crystals of the complex of bovine a-thrombin with 
recombinant hirudin variant 1 have space group C22Z1 
with cel! constants a = 59.11, b = 102.62, and c = 
143.26 A. The orientation and position of the thrombin 
component was determined by molecular replacement 
and the hirudin molecule was  fit  in 21F0J - lFel electron 
density maps. The structure was  refined by restrained 
least-squares and simulated annealing to R = 0.161 at 
2.8-A resolution. The binding of hirudin to thrombin 
is generally similar to that observed in the crystals of 
human thrombin-hirudin. Several differences in the 
interactions of the COOH-terminal polypeptide of hi- 
rudin, specifically of residues Asp-55h,  Phe-56h, Glu- 
57h, and Glu-58h, and a few differences in the  inter- 
actions of the hirudin core,  specifically of residues Asp- 
Sh,  Ser-19h, and Asn-ZOh, with thrombin from human 
thrombin-hirudin suggest that there is some flexibility 
in the binding of these 2 molecules. Most of the residues 
in the 9 subsites that bind fibrinopeptide A,-,, to 
thrombin also interact with  the NH2-terminal domain 
of hirudin. The S1 subsite is a notable exception in that 
only 1 of its 6 residues, namely Ser-214, interacts  with 
hirudin. The only difference  between human and bo- 
vine thrombins that appears to influence the binding 
of hirudin is the replacement of Lys-149E  by  an acidic 
glutamate in the bovine enzyme. 
a-Thrombin  (EC 3.4.21.5) is a serine  protease  with a  high 
specificity for arginine bonds that plays a central role in 
thrombosis  and hemostasis. I t  is  the  product of prothrombin 
cleavage by factor  Xa  in  the  final  step of the blood clotting 
cascade (reviewed by Mann, 1987; Davie et al., 1991). During 
clotting,  a-thrombin  converts fibrinogen into  fibrin by remov- 
ing fibrinopeptide  A  from the  Aa-chain  and  fibrinopeptide B 
from  the BP-chains of fibrinogen. Thrombin also functions  as 
a major  regulator of hemostasis  (Fenton, 1986; Davie et al., 
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1991, and references therein).  Free  thrombin accelerates clot- 
ting by activating  platelets  and key enzymes in  the  clotting 
cascade, such  as  factor V, factor  VIII,  factor  XI,  and  factor 
XIII, whereas thrombin  bound  to  thrombomodulin  attenuates 
clotting by activating  protein C, which then  inactivates  factors 
Va and VIIIa (Esmon, 1987; Dittman  and Majerus,  1990). 
a-Thrombin  consists of two  polypeptide chains, A and  B, 
connected  through a single  disulfide  bond.  Bovine a-thrombin 
has 49 amino acid  residues in  the A-chain and 259 residues 
in the B-chain (Magnusson et al., 1975; MacGillivray and 
Davie, 1984; Walz et al., 1986) whereas human a-thrombin 
has 36 residues, after the loss of a tridecapeptide during 
activation from prothrombin,  in  the  A-chain, of which 27 are 
identical  with  those  in bovine thrombin,  and 259 in  the  B- 
chain, of which 225 are identical (Butkowski et al., 1977; 
Degan et al., 1983; Walz et al., 1986). The  B-chain  contains a 
carbohydrate at Asn-6OG and  the active site residues  His-57, 
Asp-108, and Ser-195.’ 
The  most  potent  natural  inhibitor of thrombin known is 
hirudin, which is a small  protein  containing 65 residues and 
3 disulfide bonds  that  is i olated from  the  glandular  secretions 
of the leech Hirudo medicinalis (Markwardt, 1970). The dis- 
sociation constants  for  the  noncovalent, equimolar complex 
of hirudin  with bovine thrombin  or  with  human  thrombin  are 
3.0 p~ and 0.3 PM, respectively (Dodt et al., 1988, 1990). 
Hirudin blocks or greatly attenuates  thrombin  activity  toward 
fibrinogen, platelets, clotting factors, thrombomodulin, and 
monocytes.  Because hirudin  reacts only with  thrombin, is well 
tolerated by the  immune  system,  and  has  no hemorrhagic  side 
effects, it  is a potentially valuable drug for thromboembolic 
disorders (Markwardt, 1991). The three-dimensional struc- 
tures of the  amino-terminal  domain of two recombinant  hi- 
rudins have been determined  in  solution by NMR  methods 
(Clore et al., 1987; Folkers et al., 1989; Haruyama  and  Wuth- 
rich,  1989). In  both cases,  residues lh ,  31h-36h, and 49h-65h 
had  no defined structure  in solution. 
The  crystal  structures of the complexes of human  a-throm- 
bin  with  recombinant  hirudin  variants 1 (Griitter et al., 1990) 
and 2  (Rydel et al., 1990,1991)  have  been  recently determined. 
These studies reveal a mode of binding that has not been 
previously observed  for a protease  inhibitor.  The  unique fea- 
tures  are as follows. 
1) The  contact  area between hirudin  and  thrombin  in  the 
The residue numbers for thrombin in this paper  are assigned by 
homology with chymotrypsin  (Bode et  al., 1989). A suffix  denotes an 
insertion in the  thrombin sequence relative to  that of chymotrypsin. 
Sequence numbers for hirudin and fibrinopeptide residues are iden- 
tified by the suffix “h” or “f,” respectively. The prime symbol (’) 
denotes a residue number in a symmetry-related molecule. “Sn” is 
used for the enzyme subsite that binds the nth residue on the amino- 
terminal side of the scissile bond (Schechter and Berger, 1967). 
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complex is large,  which  probably accounts for the high affinity 
and selectivity of hirudin for thrombin. 2) The  first 3 residues 
of hirudin  bind at the active site of thrombin,  but  the  primary 
specificity site of thrombin  is  not occupied by hirudin. 3) The 
last 16 residues of hirudin  are  in an  extended  conformation 
and bind at  an  anion  binding exosite on  the  surface of throm- 
bin that extends from the active site and is probably the 
secondary fibrinogen binding  site. 
We undertook  the  structural  analysis of the complex be- 
tween bovine a-thrombin  and  recombinant  hirudin  variant l 
for  three reasons. The  first was to gain  more insight  into  the 
interactions between hirudin  and  thrombin at the molecular 
level using a crystal form different from that used in the 
earlier studies. The second  was to  investigate how the species 
variation of the thrombin enzyme, bovine versus human, 
affects  the  binding of hirudin at  the molecular level. The  third 
was  to  determine  the  structure of a  bovine thrombin  that was 
wholly in  the  a-form. All previously solved crystal  forms of 
bovine  thrombin have contained significant amounts of pro- 
teolytic derivatives (Martin et al., 1992). In this paper, we 
report  the  determination of the  crystal  structure of the com- 
plex between bovine a-thrombin and recombinant hirudin 
variant 1 and a  comparison of this  structure  with  those of the 
human a-thrombin-hirudin complexes (Rydel et al., 1990, 
1991; Grutter  et al., 1990) and  the bovine a-thrombin- 
FPA7-162 complex (Martin  et al., 1992) reported  earlier. 
MATERIALS AND  METHODS 
Preparation of Proteins-Thrombin was prepared as previously 
described (Martin et al., 1983) and had approximately 2000 NIH 
clotting  units per mg of protein.  It was stored a t  -20 "C in  ammonium 
phosphate before  being set  up for crystallization.  Recombinant  hiru- 
pBR-CRM-CTAP-Hir plasmid  (GenBank M88535), which codes for 
din was purified from Escherichia coli cells transformed with the 
hirudin fused to a CTAP leader  sequence (Waleh  et  al., 1992).  After 
the leader sequence had been removed with cyanogen bromide, the 
hirudin molecule was purified by high performance liquid chromatog- 
raphy  on reverse phase columns (Winant  et  al., 1991). The recombi- 
nant protein, which lacks the  sulfate group on Tyr-63h that is 
responsible for a 3-10-fold increase in the  affinity of leech hirudin 
for  thrombin,  had  the  same  affinity  as desulfated hirudin from natural 
sources  (Stone  and Hofsteenge, 1986; Winant  et al.,  1991). 
Crystallization-The complex was prepared by mixing bovine a- 
thrombin  and  recombinant  hirudin a t  a molar  ratio 1:1.5. The  crystals 
were grown by the hanging drop method at 22 "C from reservoirs 
containing 29% PEG  4000,250 mM sodium phosphate buffer, pH 4.7, 
94 mM NaC1, and 0.005% NaN?.  The  initial  thrombin-hirudin  con- 
centration  in  the  drop was 7  mg/ml.  Polyacrylamide gel electropho- 
resis (Laemmli, 1970) on a crystal dissolved in 1% sodium dodecyl 
sulfate  solution  (Martin  et al., 1992) showed that no conversion of 
the  a-thrombin  to  the @, 6 , or y proteolytic derivatives  had occurred 
during the crystallization. This conversion has occurred a t  least 
partially in all other crystals of bovine a-thrombin with substrate 
analogs or inhibitors that we have grown in our laboratory. The 
crystalsoare  orthorhombic, cell constants a = 59.11, b = 102.62, c = 
143.26 A, space group C222] with 1 molecule per asymmetric unit. 
The crystals of the human thrombin-hirudin complexes are tetra- 
gonal, P43212 (Rydel  et al., 1990; Grutter  et al.,  1990). 
Data Collection-Intensity data were measured a t  22 "C on  the two 
largest crystals (approximate dimensions 0.40 X 0.20 X 0.05 mm) 
using a Siemens  area  detector  with a  Rigaku  RU200H rotating  anode 
x-ray source and  Supper  graphite  monochromator  operated a t  40 kV 
and 70  mA. The  radiation used was CuKa.  Two "sweeps" were made 
for  the  first  crystal,  one for the second. Each covered  110" in w with 
440 frames of data.  In  the  first  crystal,  the 6 angle  was incremented 
by 70" between sweeps. Each  frame was measured for  5 min  to  ensure 
that  it  contained  at  least 1 million total  counts. 19008 measurements 
with I > u were merged, scaled, and averaged with the  XENGEN 
The  abbreviations used  are: FPA7-16, residues 7-16 of  fibrinopep- 
tide A from the Aa-chain of human fibrinogen; CTAP, connective 
tissue activating protein 111; PPACK, D-phenyl-L-prolyl-L-arginyl 
chloromethyl ketone. 
package (Howard et al., 1987) to give 7688 unique reflections. 
The overall,  unweighted, absolute R.,,was 0.099.QThe fraction of ob- 
served reflections for the  shells m-7.0  A,  7.0-3.3  A, 3.3-3.0  A,  3.0-2.8 
A, and 2.8-2.6 A was 92%, 84%,  50%, 24%,  and 13%,  respectively. 
Structure Solution-The orientation  and position of the  thrombin 
component  in  the  crystal was determined by the molecular  replace- 
ment  method using the package MERLOT (Fitzgerald,  1988),  mole- 
cule  2  of  bovine a-thrombin in the complex  with  fibrinopeptide A7.d~ 
(Martin  et  al., 1992) as  the probe, and 4u data between 7.0 and 3.5 A. 
The  rotational  search was carried  out with the  fast  rotation  function 
of Crowther (1972) using  the  program  CROSUM, a radius of integra- 
tion of 20.0 A, and grid interval of 2.5" in a ,  and 5.0" in @ and y. 
Three translation functions (Crowther and Blow, 1967) were com- 
puted with the program TRNSUM covering the  entire  unit cell and 
with step size along a, b, and c of 0.02 times the cell edge. The 
molecular replacement  solution was refined  with the  R-factor  search 
of Ward  et al. (1975)  using the program RMINIM  and subsequently 
with rigid body least-squares using the program ROTLSQ (W. A. 
Hendrickson, Columbia University)  and 7.0 to 3.0 A data with IF1 2 
100. 
The  structure of the  hirudin  component was determined from 21F,,I 
- IFcI electron density maps. The refinement of the complex was 
carried  out  using  restrained  least-squares procedures with the  pro- 
grams PROLSQ and PROFFT (Agarwal, 1978; Hendrickson and 
Konnert, 1979; Finzel, 1987) and by simulated annealing with the 
program XPLOR  (Brunger, 1988). The slow cool annealing protocol 
was used with XPLOR. The dynamics temperature started out a t  
4000 K and decreased in  intervals of  25 K to a final  temperature of 0 
K  with 25 steps (0.5 fs/step) of Verlet dynamics a t  each  temperature. 
The  PROLSQ  refinement was carried  out using data 7.0 to 3.0 A  with 
IF1 > 2u. All the available data beyond 7.0 A were used for the 
XPLOR  and  PROFFT  refinements. 
Structure Analysis-Hydrogen bonds were calculated  in  QUANTA 
(Polygfn Corporation, Waltham, MA) using as criteria a distance 
of 3.5 A or less between the  donor  and  acceptor  atoms  and a value of 
90" or more for the angles centered a t  these  atoms. A hydrophobic 
contact was assumed to  exist between  2 apolar residues if they  had a 
carbon-carbon  distance of 4.0 A or less. 
RESULTS  AND  DISCUSSION 
Structure Solution-The orientation and position of the 
thrombin  component in the  crystal was strongly  indicated by 
the molecular replacement searches. It corresponded to  the 
top peak  in  all searches  with a  high  signal to noise ratio. The 
top peak in  the  rotational  search  at (a, (3, y )  = (97.50", 55.00", 
230.00") was 1.7 times larger than  the  next highest  peak. The 
top peak in  each  translation  function, corresponding to  the 
position of thrombin  in  the  unit cell at  (x, y, z )  = (0.22,  0.22, 
0.15), was 2.5 to 2.7 times larger than  the  next highest  peak. 
The R  value after  ROTLSQ was 0.357. 
Initial  refinement of the  thrombin  component using 
PROLSQ  brought  the crystallographic R-factor  to 0.282. Res- 
idues lh-31h and 37h-42h of hirudin were then  fit  into  the 
electron density of a 21F01 - IFcI Fourier map. The NMR 
model of hirudin (Folkers et al., 1989; Protein Data Bank 
entry 5HIR) facilitated the fitting process for the amino- 
terminal  domain.  Nine  alternate cycles of PROLSQ refine- 
ment followed by graphics  intervention allowed us  to build 
the  rest of the  hirudin molecule and refit parts of the  thrombin 
component. The complex was further refined with  XPLOR 
to R = 0.171. The  final  refinement of the  structure was carried 
out  with  PROFFT.  Toward  the  end of the  PROFFT refine- 
ment,  water molecules were included at  129 peaks  that were 
greater  than 2 . 9 ~  in  the lFul - IFcI Fourier map, greater  than 
0.70 in the 2 lFol - lFel Fourier map, and within hydrogen 
bonding distances from appropriate atoms. The R value a t  
the conclusion of the  refinement was 0.161 (Tables I and 11). 
The  fit of parts of the  final model to  the  electron  density  is 
illustrated  in Fig. 1. 
Except for a few residues, both  thrombin  and  hirudin  are 
well defined in  the  electron  density  maps  contoured at   the l o  
level. There is no  density for the  first 13 residues at the NH, 
17672 Thrombin-Hirudin  Complex 
TABLE I 
Refinement  statistics  from  PROFFT 
Total number of atoms 
Number of solvent atoms 
Number of observations (7-2.5 A) 
Root mean square  deviations 
Bond distances 
Angle distances 
1-4 distances 
360 peptide  planes 
40 aromatic  planes 
Chiral volumes 
Single torsion contacts 
Multiple torsion contacts 
Possible ( X . .  .Y) H-bonds 
Planar torsion angles 
Staggered torsion angles 
Orthonormal  torsion angles 
2996 
129 
6958 
0.020 '$ 
0.042 4 
0.040 4 
0.011 A 
0.006 8, 
0.15lOA3 
0.33 4 
0.36 A 
2.8" 
24.1" 
29.8" 
0.22 4 
TABLE I1 
Final  R-factors  from  PROFFT as a function of resolution 
Reflections R.hd   E lohe re  
A 
6.0" 398 0.198 0.198 
5.0 805 0.169 0.178 
4.0 1659 0.135 0.151 
3.5 1470 0.150 0.150 
3.0 1864 0.174 0.156 
2.8 409 0.225 0.158 
2.5 353 0.270 0.161 
Reflections beyond 7.0 A are not included. 
45h 0 (Fig. 2),  the two  hydrogen bonds from  Lys-47h NZ to 
Thr-4h OG1 and Asp-5h 0 (Table 111), and  the hydrophobic 
contact between Pro-46h  and Leu-13h.  Gln-49h through  Pro- 
60hoform  two extended  stretches of chain, each  approximately 
15 A long, with a bend at  Gly-54h.  A type IV reverse turn for 
Glu-6lh  through Leu-64h (Table IV) gave the  best fit for the 
existing density. 
In  solution, only  residues  2h through 30h and 37h through 
48h of hirudin  are  ordered  (Folkers et al., 1989; Haruyama 
and  Wuthrich, 1989).  A superposition of the C, atoms of the 
structure determined by NMR (Folkers et al., 1989) with 
residues 5h-30h and 37h-48h of hirudin  in  the  crystal complex 
using the program ALIGN (G. Cohen, NIH; SFtow et al., 
1986) gave a  root mean  square difference of 0.83 A. When all 
atoms were included in thf superposition, the root mean 
square difference was 1.39 A. These figures are comparable 
with  the  deviations from the average NMR  structure  (Folkers 
et al., 1989),  suggesting that  the overall structure of the NH,- 
terminal  domain of hirudin changes little upon association 
with thrombin  and  subsequent  crystallization (Fig. 3). A few 
large changes of 5 8, or more  relative to  the  NMR  structure 
occur in  the side chains of Asp-5h,  which forms  salt bridges 
with Arg-221A; Asn-l2h, which is located in  the  interior of 
hirudin; Lys-27h, which is on  the surface of the complex; and 
Thr-41h  and Glu-43h,  which interact with a symmetry-related 
hirudin molecule. Gly-42h,  which also has intermolecular 
contacts,  exhibits  no large differences  from the  NMR  struc- 
ture. Residues 31h through 36h,  which were disordered in  the 
NMR  studies,  are well-defined in  our  crystal  structure due to 
the only other  intermolecular  contacts involving hirudin  res- 
terminus of the A-chain nor for several atoms in the side residues 34h, 35h, 36h, and 38h with thrombin residues be- idues present  in  the  structure, namely the close contacts of 
A-chain. In  the  B-chain of thrombin,  the  density for Thr-147 which also had no fixed structure in the NMR experiments, 
through Of the loop is fragmented' and are generally well-defined in  our  c ystal  structure as the  r sult there is no density for the side chain of Leu-245 at the COOH of interactions with thrombin (see below). 
terminus. In hirudin, there is fragmented density for Gln-49h Structure of Bovine Thrombin"The model of bovine a- 
and  Ser-50h, weak, but  continuous  density for the  main  chain 
of His-5lh, Asn-52h, Glu-Glh, and Glu-62h, no density for thrombin  in  this  structure includes  residues 1H through 247. 
the CB  atoms of Glu-6lh  and  Glu-62h,  and  little  density for It  is closely similar  with  the  structures of molecules 2 and 3 
Gln-65h. of bovine a-thrombin  in  the complex with FPA7-16 (Martin et 
Structure of Hirudin-The secondary and  tertiary  struc- al., 1992). When  these 2 thrombin molecules are superimposed 
tural features that we observe for hirudin are generally in onto  the  thrombin molecule in  the  hirudin complex with the 
with  human  thrombin (Rydel et al., 1990, 1991; Griitter et al., C, atoms  is 0.55 A and 0.56 A, respectively. 
iant 1, whose sequence is shown in ~ i ~ .  2,  has a NH,- positions  in  the  hirudin  and FPA7-16 complexes of bovine a- 
terminal  domain, comprised of residues lh  through 48h, and thrombin.  The  movement of this loop in  the  fibrinopeptide 
an extended COOH-terminal polypeptide chain, comprised of complex relative to  its  position  in  human  PPACK-thrombin 
the ~ ~ ~ - ~ ~ ~ ~ i ~ ~ l  domain is largely due to the  three disulfide the active site  (Martin et al., 1992). In  this  connection,  it may 
Cys-28h,  and  cys-22h  and  cys-39h ( ~ i ~ .  3). This domain is positions  with Val-15f and Leu-Sf of the fibrinopeptide (Fig. 
also stabilized by 24 intramolecular  hydrogen bonds of which 5)  interacting,  as will be discussed later,  with  the residues Of  
13  involve only main  chain  atoms (Fig. 2) and  the  remaining the yppw loop (Fig. 6). 
11 involve side chain atoms (Table 111). Finally, there are Twenty thrombin residues are identified by ALIGN as 
close contacts between the side chains of the hydrophobic having significantly different c, positions in the hirudin 
residues  Leu-13h and  Pro-46h, Val-21h and  Tyr-3h, Ile-29h complex as opposed to the FPA7-16 complex of bovine a- 
and Val-40h, Leu-30h and Cys-Gh. The  ability of reduced and thrombin. These residues include those that are not well 
denatured  hirudin  to refold at  extremely  high concentrations defined either  in  the  present  structure o  in the fibrinopeptide 
and in the presence of a high concentration of guanidine structure, or in  both,  such  as  Thr-147  through Ala-149D of 
hydrochloride (Johnson et al., 1991) may result from the the  autolysis loop, the  termini of the A-chain, and  the COOH 
highly  compact nature of the  hirudin core and  its  stabilization terminus of the B-chain. Glu-149E of the autolysis loop 
by numerous intramolecular  contacts.  Table IV summarizes interacts with  a symmetry-related molecule in  crystals of the 
the secondary structural elements of hirudin. The COOH hirudin complex and is displaced by 2.5 and 2.4 A  relative to 
terminus of the  hirudin core folds back to  the  NH,  terminus molecules 2 and 3, respectively, of FPA7-16 tbrombin. Also, 
with  the  main  chain hydrogen bond from  Asn-12h  N to  Thr- small  displacements  ranging from 1.3  to 1.9 A are observed 
chains Of G1u-14L and Arg-15 at the terminus Of the  longing to a symmetry-related complex. Residues  49h-65h, 
agreement  with  the published descriptions of the complexes program the rms diJference between corresponding 
1990). In the complex with bovine a-thrombin, hirudin var- Residues 60A through 60D (the yppw loop) OCCUPY 
residues 49h through 65h  (Figs.  3 and 4). The  compactness of has been attributed  to  the presence of the  fibrinopeptide  in 
bridges formed between Cys-6h and cys-14h, cys-16h and be noted that Val-lh and Leu-13h Of hirudin OCCUPY similar 
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a 
a 
FIG. 1. Stereo views of  the 21F,I - IFcI electron  density map for residues l h  through 3h of hirudin, contoured at 1.40 (a), 
and  residues 57h of hirudin and 75 of thrombin, contoured at 1.20 (b ) .  The  salt bridge Arg-75 NE. . .Glu-57h OEl is illustrated  in b. 
Any  unaccounted  density  in  these figures corresponds  to residues that have  been omitted for clarity. 
for Gly-186A and Ser-36A through Gln-38. These residues are 
on  the surface of thrombin  but  do  not  interact  with  symmetry- 
related molecules, although  Gln-38  interacts  with  Phe-56h  in 
its own complex (Fig. 7). 
Interactions  between  Hirudin  and  Thrombin-The earlier 
crystallographic  studies (Rydel et al., 1990, 1991; Grutter et 
al., 1990) showed that the mode of binding of hirudin to 
thrombin  is  unique  among  other  inhibitors of serine  proteases. 
Most  inhibitors  interact  with  their  target enzymes, mainly  in 
the region of the active site. In contrast, hirudin interacts 
with thrombin over an extended area, both within and far 
from  the active site. Of the 65  residues of hirudin, 27 actually 
contact thrombin. The total solvent-accessible surface area 
buried in the interaction between thrombin and hirudin is 
3775 or 2.6 times  the  surface  area  buried  in  the  interaction 
between trypsin and the 14 residues of bovine pancrea$ic 
trypsin  inhibitor  that  actually  contact  rypsin (1452 A’; 
Ruehlmann et al., 1973; Janin  and  Chothia, 1976; Huber  and 
Bode,  1978). The solvent-accessible  surface area  buried in the 
interaction between thrombin  and  the 10  residues of FPA7-16 
is 1318 2 (Martin et al., 1992). 
The NH2-terminal 3 residues of hirudin, Val-lh, Val-2h, 
and  Tyr-3h,  bind in the active site  to Ser-214 through Gly- 
219 (Fig. 6)  as a parallel (3-structure that  contains 4 hydrogen 
bonds, namely Val-lh N-Ser-214 0 (2.79 A), Gly-216 N+ 
Val-lh 0 (2.75 A), TyrD3h N-Gly-216 0 (2.69 A), and Gly- 
219 N-Tyr-3h 0 (3.04 A). As noted  in previous studies (Rydel 
et al., 1990,1991;  Grutter et al., 1990),  this  interaction is quite 
novel in  that  other  serine  protease  inhibitor complexes (Huber 
and Bode, 1978; Read  and  James, 1986; Bode et al., 1989) and 
the fibrinopeptide complex (Martin et al., 1992)  have an 
antiparallel p structure.  The side chains of Val-lh  and  Tyr- 
3h project into  the  “apolar  binding  site”  (Berliner  and  Shen, 
1977; Bing et al., 1981; Sonder  and  Fenton, 1984) where Val- 
l h  makes close contacts  with Trp-GOD and Tyr-GOA, and  Tyr- 
3h  makes close contacts  with  Trp-215.  The hydrophobic na- 
ture of the region about  Trp-215  explains  the increase in K, 
that accompanies the hydroxyl-group ionization of Tyr-3h 
upon  nitration  (Winant et al., 1991) and  the decrease in K, 
upon  substitution of Tyr-3h  with  phenylalanine or tryptophan 
(Lazar et al., 1991). 
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The  interactions of the  NH2-terminal  tripeptide of hirudin 
with thrombin are similar in the present structure and in 
human  thrombin-hirudin (Rydel et al., 1990, 1991; Griitter et 
al., 1990). However, in the human complexes, the amino- 
terminal group of hirudin  forms two  hydrogen bonds  to  throm- 
bin. One hydrogen bond is to  the carbonyl oxygen of Ser-214, 
as in the  present  structure.  The second is to  the  catalytic  Ser- 
195 in the  structure  done  at  pH 4.5 (Rydel et al., 1991) and  to 
the catalytic His-57 in the structure done at neutral pH 
(Griitter et al., 1990). The  latter hydrogen bond  is  not possible 
in  the bovine thrombin-hirudin  crystals which were grown at  
pH 4.7. At this pH, His-57 is most likely protonated and 
cannot  function  as a hydrogen bond acceptor. However, we 
also do not observe  a  hydrogen bond  to  Ser-195  in  the  present 
structure.  This  observation suggests that a  second  hydrogen 
bond for the amino-terminal group is not essential for the 
binding of hirudin  to  thrombin. 
Beyond Tyr-3h,  the  interactions of the  NH2-terminal  do- 
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FIG. 2. Amino acid  sequence and main chain hydrogen 
bonds of hirudin. Arcs represent reverse turns. 
main of hirudin with thrombin involve three salt bridges, 
three hydrogen bonds,  and two hydrophobic p a k  The  salt 
bridges are Arg-173 NH1..  .Glu-l7h OE2 (3.52 A), Arg-221A 
NH1.. .Asp-5h OD1 (2.93 A), and Arg-221A NH2.. .Asp-5h 
OD1 (3.08A). Tbe  three hydrogen bonds are Lys-22t NZ+ 
Ser-19h 0 (3.33 A), Lys-224 NZ-Asn-2Oh OD1 (3.38 A),  and 
Val-2lh N-Glu-217 OE2 (3.11 A). The two hydrophobic 
interactions involve Leu-13h with Pro-6OC and  Val-2lh with 
Ile-174  (Fig. 6). 
In  contrast  to  the  present  structure, Asp-5h and Arg-221A 
in  human  thrombin-hirudin  (Rydel et al., 1991) interact with 
only one salt bridge contact and Lys-224 NZ is hydrogen 
bonded  only to  Ser-19h OG. Since  these residues are  on  the 
surface of the complex and  do  not  interact with symmetry- 
related molecules, it  is possible that  there is some  flexibility 
in the  binding of residues 4h through 48h of the  hirudin core 
to  thrombin. 
Modifications  within the  first 5 amino-terminal residues of 
hirudin  can reduce the  affinity  with  thrombin by 2 to 6 orders 
of magnitude  (Lazar et al., 1991). These  changes affect  direct 
interactions between hirudin  and  the active site  and  the apolar 
binding site of thrombin. However, the large reduction in 
affinity suggests that  these  changes also disrupt  other  stabi- 
lizing interactions  (Lazar et al., 1991), such  as  the  salt link 
between  Asp-5h and Arg-221A and  the two hydrogen bonds 
from  Lys-47h to  Thr-4h  and Asp-5h in  the  present  structure 
(Table 111). 
It is interesting  that  the  NH2-terminal domain of hirudin 
interacts  with most of the residues  which  define the 9 subsites 
that  bind fibrinogen to  thrombin.  Thus, Trp-GOD that  con- 
tacts  Val-lh  is  part of S2, Gly-216 that  interacts  as a parallel 
(I-strand  with  Val-lh  and  Tyr-3h  corresponds  to  S3, Arg-173 
that  makes a salt bridge with Glu-17h  corresponds to S6, Pro- 
60C that  interacts with  Leu-13h is part of S8 but was inad- 
vertently  omitted by Martin et al. (1992), Tyr-GOA that also 
contacts  Val-lh is part of S8 and  S9,  and Ile-174 and Trp- 
215, which interact with Val-2lh and Tyr-3h, respectively, 
are part of S9. The S1 subsite, which is defined by the 6 
thrombin residues that interact with Arg-16f, is the major 
exception in that only Ser-214 also interacts with hirudin. 
Subsites S4, S5, and S7 do not exist in that no thrombin 
residues interact  with  the  corresponding residues in FPA7-1fi. 
Martin et al. (1992) discuss the  interactions of fibrinogen 
with the  apolar  binding  site of thrombin  in  terms of a  hydro- 
phobic cage about  Phe-8f  that is formed by thrombin residues 
Tyr-GOA,  Pro-GOC,  Trp-GOD, Leu-99, Ile-174, and Trp-215 
and fibrinogen residues Leu-Sf, Gly 13f, and Val-15f. When 
the structures of the hirudin and FPA7-1fi complexes with 
FIG. 3. A stereo view of the C a  
structure of the NHz-terminal do- 
main of hirudin in  the  crystal (thick 
lines) and in solution (thin lines). 
The three disulfide bridges of this do- 
main  are also  shown. The  solution  struc- 
ture  has been  superimposed on  the  crys- 
tal  structure  on  the basis of the C a  co- 
ordinates of residues 5h  through 30h and 
ALIGN. 
37h  through 48h with the program 
Thrombin-Hirudin Complex 17675 
FIG. 4. A stereo view of the Ca 
structure of the hirudin-thrombin 
complex. Thick  lines represent  hirudin, 
thin lines represent  thrombin. 
TABLE I11 
Hydrogen  bonds  involving side chain  atoms  in  the  NH2-terminal 
domain of hirudin 
Donor  Acceptor  Distance 
A 
Thr-7h N Gln-llh  OEl 3.06 
Gln-l lh  NE2 Thr-7h  OG1 3.20 
Asp-12h  ND2 Gly-23h 0 3.21 
A~p-12h ND2 Asn-26h 0 2.87 
Asn-20h  ND2 Glu-17h 0 3.14 
Gln-24h NE2 Asp-12h  OD1 3.15 
Lys-27h NZ Thr-41h 0 3.03 
Gly-31h  N Asn-37h OD1 3.40 
Cys-39h  N Glu-17h OEl 3.47 
Lys-47h NZ Thr-4h OG1 3.09 
Lvs-47h  NZ Asp-Sh 0 2.62 
TABLE IV 
Secondary  structural  elements of hirudin 
Residues  Secondarv  structure 
Thr-4h  through Cys-6h;  Cys-14h 
Cys-l4h  through Cys-16h; Asn-2Oh 
Asn-26h  through Leu-30h;  Asn-37h 
Thr-45h  through  Pro-48h 
Glu-8h  through Gln-l lh  
Glu-l7h  through Asn-2Oh 
Gly-23h  through Asn-26h 
Ser-32h  through Glu-35h 
Glu-6lh  through Leu-64h 
through Cys-16h 
through Cys-22h 
through  Thr-41h 
Parallel p 
Anti-parallel p ladderb 
Anti-parallel p ladder 
Polyproline I1 helix 
11 reverse turn'.d 
11' reverse turn'*d 
11 reverse  turn'.d 
I1 reverse turn'.' 
IV reverse turn'se 
"The Cys-6h N-Leu-15h-0 hydrogen bond of 3.63 A is slightly 
longer than  our cutoff of 3.5 A but  it  has been  included as part of the 
ladder. 
Thr-4h  through Cys-6h,  Cys-14h through Cys-16h, and Asn-2Oh 
through Cys-22h  form an approximate, mixed 0 pleated  sheet. 
' Chou and  Fasman, 1977. 
" Reverse turn  with a  hydrogen  bond. 
Reverse turn  without a  hydrogen bond. 
thrombin are superimposed with ALIGN (Fig. 5 ) ,  Leu-13h 
and  Val-lh occupy the  same  positions relative to  thrombin  as 
Leu-Sf and Val-15f of the fibrinopeptide. Further,  Tyr-3h  is 
close to  Phe-8f  and  intersects  the  peptide  bond between  Gly- 
13f and Gly-14f. Leu-13h and  Val-lh replace Leu-Sf and Val- 
15f in  the  cluster,  and  Tyr-3h replaces Phe-8f  and Gly-13f. 
The hydrophobic cluster  in  the  hirudin  structure  contains  an 
additional residue, Val-2lh (Fig. 6), which  occupies  essentially 
the  same  position  as Gly-12f of the fibrinopeptide (Fig. 5)  but 
has a bulky  side chain  that  can  interact  with Ile-174. 
The COOH-terminal peptide of hirudin  binds  on  the  surface 
of thrombin (Fig. 4) between the two loops formed by Phe-34 
through Leu-41 and Lys-70 through Glu-80. This region is 
rich  in positively  charged  side chains  and  has been  considered 
in  the  earlier crystallographic studies  (Rydel et al., 1990,1991; 
Griitter et al., 1990) to be the secondary binding site for 
fibrinogen. In  the  first  segment of extended  chain, Asn-52h 
OD1 forms a  hydrogen bond  with Asn-143  ND2 (3.34 A) apd 
Asp-53h OD2 forms a salt bridge with Arg-73 NH2 (2.61 A). 
In  the second segment, Asp-55h makes two salt bridge con- 
tacts  with Arg-73, namely Arg-73 NH2. . .Asp-55h OD2 (4.93 
A) and Arg-73 NH1. . .Asp-55h OD1 (4.94 A). The N atom-of 
Phe-56h  makes a  hydrogen bond  with  Gln-38 OEl (3.12 A). 
Its  phenyl side chain  is sandwiched  between the  ring of Phe- 
34 and  the CB-CG2 bond of Thr-74,  making close contacts 
with  Phe-34  and Leu-40. The  stacking of the two phenylala- 
nine rings has  the  characteristic edge-on pattern  (Burley  and 
Petsko, 1985). Glu-57h is engaged ip two hydrogen bond 
contacts,  Glu-57b  N+Thr-74 0 (3.74 A) and  Tyr-76 N+Glu- 
57h OEl  (3.78 A), and a salt bridge, Arg-75 NE.. .Glu-57h 
OEl  (3.46 A) (Fig. 1). Leu-65, Ile-82, and Tyr-76 form a 
hydrophobic  cavity on  the surface of thrombin  that accom- 
modates  the side chains of the hydrophobic residues at  the 
COOH terminus of hirudin -Ile-59h, Pro-6Oh, Tyr-63h,  and 
Leu-64h.  Ile-59h contacts  Tyr-76  and Ile-82, Pro-6Oh contacts 
Tyr-76,  and  Tyr-63h  contacts Leu-65 and Ile-82, as well as 
Ile-59h and Pro-6Oh. 
The  fact  that  the hydroxyl group of Tyr-63h is not involved 
in any stabilizing interactions with thrombin explains the 
insignificant difference in binding energy when Tyr-63h in 
recombinant  hirudin is replaced by phenylalanine  (Betz et al., 
1991). Iodination or nitration of Tyr-63h reduces the  pK of 
the hydroxyl  group and increases the  affinity of hirudin for 
human  thrombin by 3-10-fold, as  reported by Winant et al. 
(1991), who suggested that  the negatively charged hydroxyl 
group on the modified tyrosine ring effectively mimics the 
acidic sulfatotyrosine residue in leech hirudin.  In  the  present 
structure,  the hydroxyl  group of Tyr-63h is located 4.95 A and 
4.72 A, respectively, from  the hydroxyl  group of Tyr-76  and 
the  amide  nitrogen of Ile-82 that  make hydrogen bonds with 
sulfate oxygens on  Tyr-63h  in  the complex of sulfated hirugen 
with human a-thrombin (Skrzypczak-Jankun et al., 1991). 
Single  bond  rotations  cannot  bring  these groups  within  hy- 
drogen bonding  distance  without  creating  steric conflicts  with 
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FIG. 5. A stereo view of the resi- 
dues of hirudin (thick  lines) that are 
near residues of fibrinopeptide A 
(thin  lines) bound to thrombin. 
\ '  / \ / P 
\ 
I 99 Y '  
FIG. 6. A stereo view of the interactions of the NHz-terminal tripeptide of hirudin with thrombin. Residues 13h and 21h of 
hirudin that  interact with the apolar  binding site of thrombin  are also shown. Thick  lines represent  hirudin, thin  lines represent thrombin, 
and dashed  lines represent hydrogen bonds. 
nearby  atoms. However, in  the  present  structure,  the  amino 
group of Lys-81 can be brought  within 3.0 A from  the hydroxyl 
group of Tyr-63h by single bond  rotations,  and  it  is possible 
that these two groups  form a favorable ion  pair  in  the  nitrated 
or iodinated structure. This proposal is supported by an 
alternative  interpretation of the  electron  density of the  sul- 
fated hirugen structure  (Skrzypczak-Jankun et al., 1991) that 
places  the side chain of Lys-81 in  the  density  attributed  to 
two waters involved in a  hydrogen bonding  network  with  the 
third  sulfate oxygen. 
There  are several differences in  the polar interactions of 
the COOH-terminal polypeptide of hirudin with thrombin 
between the  present  structure  and  that of human  thrombin- 
hirudin (Rydel et al., 1991). First,  the carboxyl atoms of Asp- 
55h  are  approximately 2 A closer to  the guanidinium  group of 
Arg-73 in the  human  structure. Second, the hydrogen bond 
Phe-56h N-Gln-38 OEl is  not  present  in  the complex  with 
the  human enzyme. Third, Glu-57h forms a salt bridge with 
Arg-75' of a symmetry-related complex in  human  thrombin- 
hirudin  crystals,  although Glu-57h is also close to  the Arg-75 
residue in  its own complex and a salt bridge was predicted to 
occur in  solution.  In  the  present  crystal  structure, Glu-57h is 
not  near  any  symmetry-related molecules and  forms  the  pre- 
dicted intramolecular salt bridge with Arg-75. Fourth,  Glu- 
58h forms an ion pair with Arg-77A in human thrombin- 
hirudin whereas it does not  interact  with  any  thrombin resi- 
due  in  the  present  structure.  With  the exception of Glu-57h 
in  human  thrombin-hirudin,  these residues are  on  the surface 
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FIG. 7. 
t h i n  lines 
75 
II 
75 
.43 
A stereo view of the  interactions of residues 52h through  58h of hirudin  with  thrombin. Thick lines represent 
represent thrombin,  and dashed  lines represent hydrogen bonds. 
hirudin, 
of the complex and do not interact with symmetry-related Lys-149E is replaced by an acidic glutamate that cannot 
molecules. interact  with Asp-55h. This  is  the only  difference  between the 
Hirudin  binds more tightly  to  human  as  compared  to bovine two crystal  structures  that we can  with  certainty  attribute  to 
thrombin  (Dodt et al., 1988, 1990). and  hirudin-related  car-  the species variation of the  thrombin enzyme. 
boxyl-terminal  fragments  are  consistently more  effective in- 
hibitors of human  a-thrombin by almost 1 order of magnitude 
(DiMaio et al., 1990; Maraganore et al., 1989). Consequently, 
Dodt et al. (1990) speculated  that  the observed  species  differ- 
ences in the complexes of hirudin  with  human  and bovine a -  
thrombins  are exclusively due  to differences in  the  interaction 
with  the  carboxyl-terminal  hirudin region. However, we can- 
not  attribute  the differences that we observe in  the  binding 
of the  COOH-terminal  peptide of hirudin  to bovine thrombin 
to  any differences  in structure or sequence from human 
thrombin. The 2 thrombin molecules are closely similar in 
structure  (Martin et al., 1992), and  the residues  involved in 
the interactions  with  the  COOH-terminal  peptide of hirudin 
are common in  the  human  and bovine complexes. I t  is more 
likely that  these differences indicate some flexibility in  the 
binding of the COOH-terminal polypeptide of hirudin to 
thrombin. Additional support for this conclusion is provided 
by  the  structure of human  a-thrombin complexed with  sul- 
fated hirugen (Skrzypczak-Jankun et al., 1991),  which exhibits 
several differences in  the  interactions of the  COOH-terminal 
peptide  with  thrombin from both  human  and bovine throm- 
bin-hirudin complexes. In particular, only one of the NH 
groups of Arg-73 interacts  with  the  carboxylate oxygens of 
Asp-55h and,  as with buman  thrombin-hirudin,  the  distances 
are  approximately 2 A closer than  in  the  present  structure. 
The  salt bridge interaction of Glu-57h with Arg-75 is  inter- 
molecular in this structure, as in human thrombin-hirudin 
(Rydel et al., 1991), while Glu-58h appears not to interact 
with  thrombin,  as  in  the  present  structure.  Gln-38  interacts 
with Glu-57h in the hirugen structure,  with  Phe-56h  in  our 
structure  and  with  no residue in  human  thrombin-hirudin.  In 
human  thrombin-hirudin  (Rydel t al., 1991), Lys-149E makes 
a salt bridge contact with Asp-55h. In the bovine enzyme, 
. .  
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